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Introduction {#sec1}
============

USP14 is a deubiquitinating enzyme (DUB) involved in degradation of protein substrates by cleavage and trimming of ubiquitin chains at the proteasome ([@bib16]). USP14 is highly expressed in the nervous system and its deficiency leads to progressive neurological dysfunctions including ataxia and muscle paralysis ([@bib18]). Loss of USP14 is associated with defective ubiquitin recycling and deficiency in free ubiquitin ([@bib6]). Studies in different cancer cells have revealed a role of USP14 in the degradation of specific protein substrates as shown by the use of chemical blockers ([@bib5], [@bib7]). The underlying mechanisms for the various actions of USP14 are not fully understood. USP14 is a *bona fide* proteasome-bound protein, but recent studies have established a proteasome-independent role of USP14 in the regulation of autophagy in cells ([@bib35]) and in c-jun N-terminal kinase signaling at the neuromuscular junction ([@bib31]). Previous studies have further shown that USP14 can interact with inositol-requiring enzyme 1α (IRE1α) on the ER membrane and inhibit ER-associated protein degradation ([@bib20]). We recently observed that USP14 is cytoprotective in neuronal cells by reducing protein aggregates, as observed in models of Huntington disease (HD) ([@bib12]). Part of this effect evoked by USP14 was ascribed to the ubiquitin proteasome system (UPS) and to the counteraction of IRE1α-mediated ER stress signaling. However, the precise mechanisms underlying the different cellular roles of USP14 and in the pathology of various diseases are not fully understood.

In the present work, we have used a proteomic approach to search for interacting partners of USP14 in the context of neuronal cells. To study the complementary roles of USP14 in a proteasome-free context, we constructed UBL domain mutant USP14 with a reduced ability to bind to PSMD2/RPN1 in the proteasome 19S regulatory particle (RP). We subsequently utilized inhibitors of proteasome causing dissociation of USP14 from PSMD2, a component of the proteasome 19S RP. Upon proteasome inhibition, USP14 interacted with HSC70/HSPA8 in neuronal cells, whereas the UBL mutant, W58A-USP14, bound the chaperone avidly even without proteasome blockage. The small molecule compound, VER-155008, that inhibits HSC70 affected the levels of USP14 in cells, and the interaction of USP14 with HSC70 reciprocally regulated their protein levels. Furthermore, we showed that USP14 can interact with other proteins in the cell, including unspliced X-box binding protein-1 that forms aggresome-like induced structures (called ALIS) in the neuronal cells following proteasome inhibition. These structures were sensitive to HSC70 inhibition by VER-155008 and the levels of USP14, as shown in neuroblastoma cell lines after downregulation of USP14 using shRNA. In mutant huntingtin (Htt)-expressing striatal cells with reduced USP14 levels, the XBP1u positive ALIS also decreased. As reported earlier, USP14 also interacted with the ER signaling protein, IRE1α, affecting its phosphorylation status and endonuclease splicing activity albeit differentially upon proteasome inhibition. Most significantly, USP14 interacted with the autophagy-linked protein gamma-aminobutyric acid receptor-associated protein (GABARAP) involved in the late stage of autophagy ([@bib34]). We observed that the UBL mutant, W58A-USP14 promoted the formation of GABARAP-positive autophagosomal structures in striatal neuronal cells, a process that was reduced by the HSC70 inhibitor, VER-155008. Together these data demonstrate that USP14 and its interaction with HSC70 affect autophagy and other cellular processes in neuronal cells.

Results {#sec2}
=======

USP14 Interacts with the Proteasome 19S Subunit PSMD2 via the UBL Domain {#sec2.1}
------------------------------------------------------------------------

USP14 is an important proteasome-associated DUB that removes ubiquitin chains from protein substrates destined for degradation. However, USP14 may also have non-proteasomal functions by binding to specific proteins in the cell as shown for the IRE1α in the ER membrane ([@bib12], [@bib20]). The mechanisms and factors governing the de-attachment of USP14 from the proteasome are not fully understood. We observed that lactacystin (a chemical compound that inhibits the proteasome) caused release of USP14 from PSMD2 in the proteasome 19S RP in SH-SY5Y human neuroblastoma cells ([Figure 1](#fig1){ref-type="fig"}A). To study the structural requirement for USP14 binding to the proteasome 19S subunit, we focused on the amino-terminal ubiquitin-like domain (UBL) with a stretch of amino acids 54-60 that is conserved between species ([Figure 1](#fig1){ref-type="fig"}B). Amino acid 58 (tryptophan, W) in the UBL domain was subsequently mutated to alanine (A) to generate the USP14 mutant construct, W58A-USP14 ([Figure 1](#fig1){ref-type="fig"}C). Immunoprecipitation experiments in SH-SY5Y neuroblastoma cells using the Flag-tagged USP14 constructs revealed that wild-type USP14 avidly interacted with the protein PSMD2/RPN1 of the proteasome 19S RP, whereas the UBL-mutant W58A-USP14 construct did not ([Figure 1](#fig1){ref-type="fig"}D). In order to investigate the catalytic activity of the generated mutant, we employed the ubiquitin-vinyl methyl ester (Ub-VME) substrate assay ([@bib3]). The mutant USP14 construct showed no significant deubiquitinating activity in this assay performed with mouse neuroblastoma cells ([Figure 1](#fig1){ref-type="fig"}E). In contrast, wild-type USP14 was active as indicated by the presence of an additional band corresponding to the Ub-VME substrate bound to the catalytic site of USP14 ([Figure 1](#fig1){ref-type="fig"}E, arrow). These results show that amino acid 58 in the UBL region is vital for the interaction of USP14 with the PSMD2/RPN1 in the proteasome 19S RP.Figure 1Proteasome Inhibition Disrupts the Association of USP14 with PSMD2 in the Proteasome 19S Subunit(A) SH-SY5Y cells overexpressing Flag-WT-USP14 were treated with DMSO or lactacystin (5 μM, 6 h) and subjected to immunoprecipitation. The complexes were analyzed by immunoblotting for PSMD2 of the proteasome 19S regulatory particle and Flag. Densitometry ratio of the PSMD2-USP14 interaction is presented in the right panel.(B) Protein sequence of USP14 UBL domain is conserved among species.(C) Tryptophan (W) mutated to alanine (A) in W58A-USP14 sequence is underlined.(D) Immunoprecipitation of Flag-WT-USP14 or Flag-W58A-USP14 constructs with Flag antibody and analyzed by immunoblotting for PSMD2 and Flag.(E) Cell lysates of Neuro2A cell overexpressing Flag-WT-USP14, Flag-C114A-USP14, or Flag-W58A-USP14 were incubated with the Ub-VME substrate for 3 h to assess DUB activity. The mixture was analyzed by immunoblotting for Flag, to detect the substrate-bound DUBs (shows as an additional band on the IB, marked by an arrow; star marks the overexpressed Flag constructs).Abbreviations: USP14, ubiquitin-specific protease-14; WT, wild-type; PSMD2, 26S proteasome regulatory subunit 2; UBL, ubiquitin-like; Ub-VME, ubiquitin-vinyl methyl ester; DUB, deubiquitinating enzyme; IB, immunoblotting; IP, immunoprecipitation. (A) n = 3, \*\*- p ≤ 0.01 Student\'s t-test.

Identification of HSC70 as Interacting Partner of USP14 {#sec2.2}
-------------------------------------------------------

In order to identify USP14 interacting partners, we designed a proteomics strategy using a novel mammalian retroviral-based expression vector pES-NTAP-Puro (a modified version of pCeMM-NTAP(SG)-Gw vector, EURO-SCARF) (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). We generated USP14-NTAP-Puro stably expressing SH-SY5Y cell lines and employed tandem affinity purification (TAP) ([@bib4]) followed by tandem MS sequencing, bioinformatic analysis, and functional validation of selected interacting partners for USP14 ([Figure S2](#mmc1){ref-type="supplementary-material"}) ([@bib24], [@bib25]). The details of NTAP-puro construction, in which the IRES-GFP cassette has been replaced with IRES-Puro, allowing selection on puromycin are shown in [Figure S1](#mmc1){ref-type="supplementary-material"}. The functionality of pES-NTAP-Puro was verified by cloning and expression of human USP14 in SH-SY5Y cells. Following SAINT filtering, we identified in total 26 USP14 IP, 23 of which form the 26S proteasomal assembly ([Figure 2](#fig2){ref-type="fig"}A). A list of the USP14 IP, isolated from SH-SY5Y USP14-NTAP-Puro stable cells, is shown in [Table S1.](#mmc1){ref-type="supplementary-material"} Nineteen (73%) USP14 high-confidence IP (HCIP) were previously determined by a variety of methods including affinity-capture MS, affinity-capture Western, or co-fractionation ([Biogrid/homo-sapiens/usp14](https://thebiogrid.org/114551/summary/homo-sapiens/usp14.html){#intref0010}). In addition, we identified HSPA8/HSC70, heat shock 71 kDa protein 8 as an interactor of USP14 ([Figure 2](#fig2){ref-type="fig"}A and [Table S1](#mmc1){ref-type="supplementary-material"}). In order to functionally validate the interaction of USP14 with HSC70, SH-SY5Y cells stably expressing Flag-HA-GFP and Flag-HA-WT-USP14 were generated. The cells were lysed and protein levels of HSC70 analyzed using immunoblotting. Stable expression of WT-USP14 increased the protein levels of HSC70 ([Figure 2](#fig2){ref-type="fig"}B). Furthermore, transient overexpression of WT-USP14 in neuroblastoma cells also increased HSC70 protein levels, and this effect was more pronounced for the W58A-USP14 mutant ([Figure 2](#fig2){ref-type="fig"}C). These results indicate that the interaction of USP14 with HSC70 increases the protein levels of the latter probably affecting its multiple cellular functions.Figure 2Proteasome Inhibition or Expression of Mutant W58A-USP14 Enhances the Association of USP14 with HSC70Affinity purification and bioinformatic analysis of USP14-interacting partners were performed as depicted in [Figure S2](#mmc1){ref-type="supplementary-material"}.(A) The identified USP14-interacting partners are depicted figuratively where most of the hits constitute the 26S proteasome complex and have previously been reported. The interaction of USP14 with HSPA8/HSC70 is depicted separately.(B and C) SH-SY5Y cell lines (B) stably expressing Flag-HA-USP14 and Flag-HA-GFP, (C) transiently expressing wild-type and mutant USP14 construct (WT-USP14 and W58A-USP14) were analyzed by immunoblotting for HSC70 and Flag expression. Actin served as loading control.SH-SY5Y cells overexpressing various USP14 constructs were treated with drugs and analyzed for the interaction with HSC70.(D) Flag-WT-USP14 and Flag-W58A-USP14 constructs.(E) Flag-WT-USP14 and treatment with the proteasome inhibitor, bortezomib (0.5 μM, 6 h). Treatment with DMSO was used as a negative control.(F) Flag-WT-USP14 or Flag-W58A-USP14 co-expressed with GFP-WT-HSC70 were treated with MG132 (20 μM, 6 h) or DMSO (negative control) and subjected to IP with anti-Flag antibodies.The immunoprecipitated complexes were analyzed by IB for HSC70 and Flag (D and E) and for GFP, and Flag (F) values represent means ± SEM, n = 3. (B) p value was calculated by student\'s t-test and (C) one-way ANOVA. \*p ≤ 0.05; \*\*\*\*p ≤ 0.0001.FASP, filter-aided sample preparation; nanoLC-MS/MS, nano-liquid chromatography coupled tandem mass spectrometry; Co-IP, co-immunoprecipitation; SAINT, significance analysis of interactome; USP14, ubiquitin-specific protease-14; WT, wild-type; IB, immunoblotting; HSPA8/HSC70, heat shock cognate 71 kDa protein; HA, hemagglutinin tag; GFP, green fluorescent protein.

Inhibition of Proteasome Affects the Interaction of USP14 with HSC70 {#sec2.3}
--------------------------------------------------------------------

To validate our findings on HSC70, we carried out co-immunoprecipitation experiments using the W58A-USP14 mutant, transiently expressed in SH-SY5Y cells. In these experiments, the mutant W58A-USP14 readily interacted with HSC70, whereas, WT-USP14 exhibited less ability to bind to the chaperone ([Figure 2](#fig2){ref-type="fig"}D). To investigate whether the association of WT-USP14 with HSC70 may require some additional stimulus, we used bortezomib to inhibit the proteasome ([Figure 2](#fig2){ref-type="fig"}E). Upon proteasome inhibition, the association of USP14 with HSC70 was clearly increased ([Figure 2](#fig2){ref-type="fig"}E, lane 3). This is likely related to the fact that inhibition of the proteasome liberates more USP14 from its binding to PSMD2 in the proteasome 19S RP ([Figure 1](#fig1){ref-type="fig"}). Thus, our findings indicate that proteasome inhibition induced an increase in association of WT-USP14 with HSC70. To further corroborate the interaction of USP14 and HSC70, we overexpressed Flag-USP14 constructs in conjunction with GFP-WT-HSC70 in SH-SY5Y cells followed by immunoprecipitations. The resulting IP complexes were analyzed by immunoblotting with anti-Flag and anti-GFP antibodies. GFP-WT-HSC70 co-immunoprecipitated with Flag-WT-USP14 and the interaction was increased in the presence of MG132 ([Figure 2](#fig2){ref-type="fig"}F). Mutant W58A-USP14 exhibited a high inherent ability to associate with HSC70, exceeding that observed with WT-USP14 after proteasome inhibition ([Figure 2](#fig2){ref-type="fig"}F). Together these results show that the interaction of USP14 with HSC70 in neuroblastoma cells is sensitive to proteasome inhibition.

USP14 Interacts with XBP1u Protein upon Proteasome Inhibition {#sec2.4}
-------------------------------------------------------------

We and others have previously shown that USP14 can bind to the ER(ER)-resident kinase, IRE1α, affecting its phosphorylation status in models of HD ([@bib12]). Activation of IRE1α mediates various signaling cascades during UPR and ER stress including the splicing of the X-box binding protein 1 (XBP1) mRNA producing the transcription factor XBP1s ([@bib19]). The unspliced mRNA is still translated into a functional protein (called XBP1u, unspliced XBP1) in higher order eukaryotes ([@bib30]). To investigate whether USP14 interacts with the XBP1 proteins, we studied endogenous USP14 in primary cortical neurons ([@bib8]). As shown by immunoprecipitation, USP14 interacted with XBP1, but only with the 29 kDa, unspliced XBP1 form (XBP1u, marked with a red star in [Figure 3](#fig3){ref-type="fig"}A) under normal conditions, and this interaction was more pronounced upon MG132-induced proteasome inhibition ([Figure 3](#fig3){ref-type="fig"}A, lane 2). To further assess this interaction, co-immunoprecipitation experiments were performed in SH-SY5Y cells expressing Myc-DDK-XBP1u followed by immunoprecipitation using anti-Flag antibody. XBP1u preferentially interacted with USP14 under conditions of proteasome inhibition by MG132 ([Figure 3](#fig3){ref-type="fig"}B). This interaction was more pronounced by overexpression of WT-USP14 leading to the appearance of HSC70 in the formed immunocomplex ([Figure 3](#fig3){ref-type="fig"}B, lane 4). This suggests the existence of a tri-partite complex of XBP1u, USP14, and HSC70 present after proteasome inhibition in the cells. Next, we performed immunoprecipitation experiments in SH-SY5Y cells using Flag-tagged USP14 constructs showing that WT-USP14 and the UBL-mutant, W58A-USP14, did not significantly bind XBP1u under unstressed control conditions ([Figure 3](#fig3){ref-type="fig"}C, lane 1 and 4). However, upon proteasome inhibition that elevates XBP1u, there was a clear interaction of XBP1u with WT-USP14 ([Figure 3](#fig3){ref-type="fig"}C, lane 3). In these experiments, addition of tunicamycin did not induce the USP14-XBP1u interaction. These results reveal that USP14 interacts with XBP1u upon inhibition of the proteasome with potential functional consequences on ER stress regulation and crosstalk between different cellular processes.Figure 3USP14 Associates with XBP1u upon Proteasome Inhibition(A) Rat primary cortical neurons were treated for 6 h with MG132 (20 μM) or DMSO, lysed, and subjected to IP utilizing anti-USP14 antibody. Right panel depicts a histogram for the densitometry ratio XBP1u (red \*)-USP14 interaction in the pull down.(B) SH-SY5Y cells overexpressing Myc-DDK-XBP1u and treated for 6 h with MG132 (20 μM) in the presence and absence of GFP-WT-USP14 were subjected to IP with anti-Flag antibody. Treatment with DMSO served as a negative control.(C) SH-SY5Y cells overexpressing Flag-WT-USP14 or Flag-W58A-USP14 were treated for 6 h with MG132 (20 μM) or tunicamycin (2.5 μg/mL) and immunoprecipitated with anti-Flag antibody. Treatment with DMSO served as negative control. Right panel depicts a histogram for the densitometry ratio of XBP1u normalized to Flag in the pull down.The complexes were analyzed by immunoblotting for (A) USP14 and XBP1 (XBP1u) (B) USP14, HSC70, and XBP1 (XBP1u), (C) XBP1 (XBP1u), and Flag. XBP1u-unspliced X-box-binding protein 1. (A) n = 4, (C) n = 3. p value was calculated by student\'s t-test (A and C). \*p ≤ 0.05; \*\*\*p ≤ 0.001.

XBP1u Forms Aggresome-like Induced Structures upon Proteasome Inhibition in Neuroblastoma Cells {#sec2.5}
-----------------------------------------------------------------------------------------------

Based on the findings above, we investigated the dynamics of XBP1u upon proteasome inhibition. Toward this goal, SH-SY5Y cells were treated with MG132 or the lysosomal inhibitor, chloroquine, followed by immunoblotting using anti-XBP1 antibody (representative immunoblot in [Figure 4](#fig4){ref-type="fig"}A depicts XBP1u detected by XBP1 antibody). MG132 induced a robust increase in protein levels of XBP1u, whereas chloroquine treatment had a minor effect on XBP1u ([Figure 4](#fig4){ref-type="fig"}A). To clarify whether USP14 influences the increase in XBP1u upon proteasome inhibition, we expressed GFP-WT-USP14 in neuroblastoma cells further treated with either MG132 or bortezomib ([Figure 4](#fig4){ref-type="fig"}B). USP14 overexpression did not affect the protein levels of XBP1u induced by these inhibitors ([Figure 4](#fig4){ref-type="fig"}B). Next, immunostainings using specific anti-XBP1u antibody were performed to assess the cellular localization of XBP1u in control and proteasome-inhibited SH-SY5Y cells ([Figure 4](#fig4){ref-type="fig"}C). We observed that XBP1u was present in aggresome-like induced structures (named here ALIS) in the MG132-treated neuroblastoma cells. We then generated stable SH-SY5Y cell lines with downregulation of USP14 using specific shRNA constructs, whereas control cells were created using scrambled shRNA. The level of USP14 protein in the USP14-shRNA cell lines was efficiently downregulated, by ∼70%--80% in comparison to control cells. Most significantly, the increase in XBP1u induced by MG132 was significantly reduced in the USP14-deficient cells ([Figure 4](#fig4){ref-type="fig"}D). Together, these findings demonstrate that XBP1u accumulates in neuroblastoma cells after proteasome inhibition and that XBP1u levels are affected by the expression of USP14.Figure 4XBP1u Is Increased upon Proteasome Inhibition and Forms ALIS Structures in Cells Regulated by USP14(A) SH-SY5Y cells treated with MG132 (20 μM), chloroquine (50 μM), or DMSO (negative control) for 6 h were analyzed by immunoblotting for the presence of XBP1u detected by XBP1 antibody. Lower panel depicts densitometry histograms for the value of XBP1u normalized to actin.(B) SH-SY5Y cells transfected with GFP-WT-USP14 or empty vector were treated with MG132 (20 μM), bortezomib (0.5 μM), or DMSO for 6 h (negative control) and analyzed for the presence of XBP1u. Immunodetection with anti-GFP and anti-actin served as transfection and loading controls, respectively. Lower panel shows XBP1u normalized to actin.(C) SH-SY5Y cells treated with MG132 (20 μM) or DMSO for 6 h were fixed and stained with anti-XBP1u antibodies. Note presence of immunopositive aggregates, named aggresome-like induced structures (ALIS, green). Nuclei were stained by Hoechst dye (blue). Scale bar, 100 μm.(D) USP14 shRNA and scramble shRNA lentivirus-infected SH-SY5Y cells were treated with MG132 (20 μM) or DMSO for 6 h. The lysates were analyzed by IB for XBP1 (XBP1u), actin, and USP14. Right panel depicts a histogram for the densitometry ratio of XBP1u normalized to actin.n = 3, p value was calculated by one-way (A and D) or two-way ANOVA (B). \*p ≤ 0.05; \*\*\*p ≤ 0.001, \*\*\*\*p ≤ 0.0001.

USP14 Levels Affect IRE1α Phosphorylation and Splicing of XBP1 {#sec2.6}
--------------------------------------------------------------

It was previously reported that XBP1u nascent polypeptide can influence the localization of its own mRNA to the ER membrane, facilitating the generation of spliced XBP1 by IRE1α ([@bib36]). Given the role of USP14 in regulation of XBP1u levels, we investigated the function of USP14 in modulating IRE1α response following proteasome inhibition. Overexpression of Flag-WT-USP14 in SH-SY5Y cells followed by immunoprecipitation showed that USP14 interacts with IRE1α upon proteasome inhibition ([Figure 5](#fig5){ref-type="fig"}A). The interaction following tunicamycin treatment was also detected, but to a significantly lesser degree, whereas the effect of MG132 was more pronounced ([Figure 5](#fig5){ref-type="fig"}A). Treatment of USP14-shRNA knock-down cell lines with MG132 produced a large increase in the phosphorylation of IRE1α as shown by the ratio of phosphorylated to total IRE1α ([Figure 5](#fig5){ref-type="fig"}B). The level of spliced XBP1 (XBP1s) was also increased following MG132 treatment; however, this increase was reduced in the USP14-deficient neuroblastoma cells ([Figure 5](#fig5){ref-type="fig"}B). Next, we investigated the effects of tunicamycin in the USP14-shRNA knock-down cell lines. Addition of tunicamycin for 6 h induced IRE1α phosphorylation and XBP1s reflecting the activation of the UPR ([Figure 5](#fig5){ref-type="fig"}C). In contrast to MG312, the effect of tunicamycin on IRE1α phosphorylation was reduced in USP14-deficient cells ([Figure 5](#fig5){ref-type="fig"}C), whereas the level of XBP1s was the same in control and USP14 downregulated cells treated with tunicamycin. This shows that the downregulation of USP14 differentially affects IRE1α signaling in the cell upon proteasome inhibition, increasing the degree of IRE1α phosphorylation, whereas reducing the levels of XBP1s.Figure 5USP14 Differentially Regulates IRE1α upon Proteasomal Inhibition(A) SH-SY5Y cells overexpressing Flag-WT-USP14 or Flag-W58A-USP14 and treated for 6 h with MG132 (20 μM) or tunicamycin (2.5 μg/mL) were subjected to IP with anti-Flag antibodies. Immunoprecipitated complexes were analyzed for the presence of IRE1α and Flag.USP14 shRNA and scramble shRNA lentivirus-infected SH-SY5Y cells were treated with (B) MG132 (20 μM) or (C) tunicamycin (2.5 μg/mL) for 6 h. Treatment with DMSO served as negative control. The lysates were analyzed for the presence of IRE1α, p-IRE1α, and XBP1s (detected by XBP1 antibody). Immunodetection with anti-USP14 and anti-actin served as a control for silencing efficiency and loading control, respectively. (B) Lower panel depicts densitometry histograms for the ratio of p-IRE1α normalized to total IRE1α and XBP1s normalized to actin. (C) Densitometry ratio of p-IRE1α normalized to total IRE1α.(B and C) n = 3, p value was calculated by two-way ANOVA. \*p ≤ 0.05; \*\*p ≤ 0.01. IRE1α, inositol-requiring protein 1α; XBP1s, spliced X-box-binding protein 1; pIRE1α, phosphorylated IRE1α.

USP14 Is Reduced in Striatal Neurons Expressing Mutant Htt Cells {#sec2.7}
----------------------------------------------------------------

We previously observed that overexpression of USP14 decreased the amount of mutant Htt aggregates in neuronal cells, partly due to its beneficial effects on reducing ER stress ([@bib12]). However, the role of endogenous USP14 in striatal neurons that are the main target in HD remained unclear. To resolve this, we cultured striatal cells expressing endogenous wild-type Htt (7Q repeats) or mutant Htt (109Q repeats) proteins ([@bib14], [@bib38]). Immunoblotting showed that USP14 levels together with HSC70 were reduced in striatal cells expressing mutant 109Q Htt compared with controls ([Figure 6](#fig6){ref-type="fig"}A). Quantitative PCR analyses done as in [@bib23]) revealed that USP14 expression was also lowered in mutant Htt cells ([Figure 6](#fig6){ref-type="fig"}C). As in neuroblastoma cells ([Figure 4](#fig4){ref-type="fig"}), treatment with MG132 induced an increase in XBP1u in control striatal cells ([Figure 6](#fig6){ref-type="fig"}B). However, this increase was significantly less pronounced in mutant Htt-expressing cells ([Figure 6](#fig6){ref-type="fig"}B). Immunostaining of these cells revealed that the formation of XBP1u containing ALIS induced by MG132 was also reduced in mutant Htt cells ([Figure 6](#fig6){ref-type="fig"}D).Figure 6Striatal Cells Expressing Mutant Htt Have Reduced Levels of USP14, HSC70, and XBP1u Aggregates(A) Striatal cells expressing 7Q (control) and 109Q (mutant) huntingtin (Htt) were subjected to immunoblotting for USP14, HSC70, and GAPDH. Lower panels represent histograms of the densitometry ratios of USP14 and HSC70, normalized to GAPDH.(B) Striatal cells expressing 7Q or 109Q Htt were treated with MG132 (20 μM, 6 h) or DMSO (control) followed by immunoblotting for XBP1u using anti-XBP1 antibody. Right panel represents the histogram for the densitometry ratio of XBP1u normalized to GAPDH.(C) qPCR was done as described in [Transparent Methods](#mmc1){ref-type="supplementary-material"}. Note reduced expression of *USP14* in 109Q Htt cells compared with 7Q Htt cells. Gene expression was normalized to *GAPDH* and controls set to 1.(D) Striatal cells were immunostained for XBP1u to show presence of XBP1u-positive ALIS induced by MG132. Note reduced immunostaining in 109Q Htt cells compared with 7Q Htt cells. Right panel represents a histogram for the average integrated intensity per XBP1u particle. Nuclei were stained by Hoechst dye (blue). Scale bar, 100 μm.In (A--D, except C) n = 3, (C) n = 5, (A--D) p value was calculated by Student\'s t-test. \*p ≤ 0.05, \*\*p ≤ 0.01, \*\*\*p ≤ 0.001. 7Q, 7-polyglutamine repeats; 109Q, 109-polyglutamine repeats; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

Inhibition of HSC70 Reduces the Cell Viability and Downregulates USP14 in Striatal Cells {#sec2.8}
----------------------------------------------------------------------------------------

Earlier reports on the role of HSC70 chaperone in neurodegenerative diseases revealed its function in disaggregating misfolded proteins and in autophagy processes ([@bib26], [@bib29]). To study the role of HSC70 in interaction with USP14, we employed VER-155008, a small molecule inhibitor of HSC70 ([@bib37]). VER-155008 induced a significant amount of cell degeneration in cultured striatal cells in a dose-dependent manner, and mutant cells expressing 109Q Htt were generally more vulnerable to the effect of VER-155008 ([Figure 7](#fig7){ref-type="fig"}A). Treatment with VER-155008 also reduced the level of USP14 in the striatal cells ([Figure 7](#fig7){ref-type="fig"}B). Further corroborating the role of HSC70 in USP14 dynamics, VER-155008 downregulated the XBP1u ALIS structures in striatal cells following proteasome inhibition ([Figure 7](#fig7){ref-type="fig"}C). Taken together, these results show that inhibition of HSC70 by VER-155008 reduced viability of striatal cells in conjunction with a decrease in USP14 and with an influence on MG132-induced XBP1u ALIS.Figure 7Chemical Inhibition of HSC70 with VER-155008 Causes Cell Death in Striatal Neuronal Cells and Downregulates USP14 Protein Levels(A) Striatal cells expressing 7Q or 109Q Htt were treated with VER-155008 (25 μM or 50 μM, 24 h). Cell viability was assessed with MTT as described in [Transparent Methods](#mmc1){ref-type="supplementary-material"}.(B) Striatal 7Q Htt cells were stimulated with VER-155008 (25 μM, 24 h) and the lysates analyzed for the presence of USP14. Right panel shows histogram for the densitometry ratio of USP14 normalized to GAPDH.(C) Striatal cells were immunostained for XBP1u to show the effect of VER-155008 on MG132-induced XBP1u ALIS in 7Q Htt-expressing cells. Nuclei were stained by Hoechst dye (blue). Scale bar, 100 μm.p value calculated by two-way ANOVA n = 4 (A), Student\'s t-test n = 3 (B). \*p ≤ 0.05, \*\*p ≤ 0.01, \*\*\*\*p ≤ 0.0001. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.Nuclei were stained by Hoechst dye (blue). Scale bar, 100 μm.

W58A-USP14 Interacts with GABARAP and Enhances the Formation of GABARAP Positive Autophagosomes that Are Regulated by VER-155008 {#sec2.9}
--------------------------------------------------------------------------------------------------------------------------------

Proteasome inhibition has been linked to an increase in compensatory autophagy establishing a functional crosstalk between the two cellular processes ([@bib15], [@bib17], [@bib27]). Several proteins including the autophagy-related protein 8 (Atg8) family, involved in the formation of the autophagosomal membrane at different stages, regulate autophagy. Mammalian Atg8 genes consist of three subfamilies: microtubule-associated protein 1 light chain 3 (LC3), γ-aminobutyric-acid-receptor-associated protein (GABARAP) and Golgi-associated ATPase enhancer of 16 kDa (GATE-16) ([@bib28]). Using co-immunoprecipitation, we studied whether USP14 can interact with GABARAP, which is involved in the maturation of autophagosomes. Results showed that there was a weak interaction of GABARAP with WT-USP14 in the neuroblastoma cells under normal conditions ([Figure 8](#fig8){ref-type="fig"}A, lane 1). However, the strength of the interaction was more pronounced upon proteasome inhibition using MG132 ([Figure 8](#fig8){ref-type="fig"}A, lane 2), and the UBL-mutant, W58A-USP14, avidly interacted with GABARAP even without addition of MG132 ([Figure 8](#fig8){ref-type="fig"}A, lane 3). Validation of the protein interaction was achieved in primary cortical neurons ([Figure 8](#fig8){ref-type="fig"}B) and striatal neuronal cells ([Figure 8](#fig8){ref-type="fig"}C), corroborating that proteasome inhibition increased the association of endogenous USP14 with GABARAP compared with controls (lane 1, [Figures 8](#fig8){ref-type="fig"}B and 8C). To study the functional consequences of the USP14-GABARAP interaction, we focused on the striatal neuronal cells expressing either 7Q Htt or 109Q mutant Htt. Immunoblotting revealed that GABARAP was downregulated in the 109Q Htt cells ([Figure 8](#fig8){ref-type="fig"}D). GABARAP, as other ATG8 family proteins, is processed to a mature form GABARAP-II, aiding in autophagosome formation, and this was reduced in the mutant 109Q cells, as shown by the densitometric ratio of GABARAP-II (mature form) to GABARAP-I (pro form) ([Figure 8](#fig8){ref-type="fig"}D, lane 3 and 4; right panel histogram). Bafilomycin is known to block the fusion of autophagosomes and lysosomes. Striatal 7Q-cells expressing W58A-USP14 and treated with bafilomycin displayed an increased conversion of GABARAP during autophagy ([Figure 8](#fig8){ref-type="fig"}E, lane 4), indicating that W58A-USP14 could regulate this process. However, in the 109Q mutant Htt cells, there was no clear increase in GABARAP processing in the presence of neither W58A-USP14 nor bafilomycin ([Figure 8](#fig8){ref-type="fig"}E, lane 8). To investigate this further, we used live cell imaging of EGFP-GABARAP positive puncta as representative of autophagosomes present in the striatal cells after different treatments ([Figures 9](#fig9){ref-type="fig"}A--9C). Striatal 7Q-expressing cells exhibited more GABARAP-positive puncta compared with 109Q-expressing cells ([Figures 9](#fig9){ref-type="fig"}A--9C). Addition of chloroquine to block lysosomal degradation increased the number of these structures, particularly in control 7Q-expressing cells ([Figure 9](#fig9){ref-type="fig"}A). W58A-USP14 expression also increased the GABARAP-positive puncta, which was further elevated by the addition of chloroquine ([Figure 9](#fig9){ref-type="fig"}A, panels 3 and 4). Next, we studied whether HSC70 could play a role in the W58A-USP14 mediated increase in GABARAP-positive puncta. Addition of VER-155008 to inhibit HSC70 blocked the increase in GABARAP-positive puncta that arose from W58A-USP14 expression ([Figure 9](#fig9){ref-type="fig"}B, panels 2 and 3). To study the GABARAP positive autophagosomal structures at a higher resolution we then employed the Nikon Eclipse Ti-E inverted wide-field microscope equipped with an environmental chamber (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). This set of imaging confirmed the increase in GABARAP-positive puncta by W58A-USP14 ([Figure 9](#fig9){ref-type="fig"}C, panel 2), as well as the decrease following the inhibition of HSC70 with VER-155008 ([Figure 9](#fig9){ref-type="fig"}C, panel 2 and 3). Together the live cell experiments demonstrate that HSC70 can influence GABARAP-positive puncta in the striatal cells and likely so via its interaction with USP14. The results further suggest that mutant Htt-expressing striatal cells have a defect in autophagy at the GABARAP-mediated autophagosome maturation level. As shown here this can be modulated by USP14 and HSC70 proteins, which can be of significance in HD and other neurodegenerative diseases accompanied by a dysfunctional autophagy.Figure 8Proteasome Inhibition or Expression of Mutant W58A-USP14 Increases Association of USP14 with GABARAP in Neuronal Cells(A) SH-SY5Y cells overexpressing Flag-WT-USP14 or Flag-W58A-USP14 together with EGFP-GABARAP were treated with MG132 (20 μM, 6 h) and subjected to IP with anti-Flag antibody. The complexes were analyzed by immunoblotting using anti-GFP and anti-Flag antibodies. Red arrow indicates IgG heavy chain band. Blue arrow indicates Flag-USP14. (Red \*)---pro form of GABARAP (GABARAP-I), (Red \*\*)---mature form of GABARAP (GABARAP-II).(B) Primary cortical neurons were treated with MG132 (20 μM, 6 h) or DMSO and subjected to IP with anti-USP14 antibody. The complexes were analyzed with anti-GABARAP and anti-USP14 antibodies. Red arrow indicates IgG heavy chain band. Blue arrow indicates USP14.(C) Striatal 7Q cells were treated with MG132 (20 μM, 6 h) or DMSO and subjected to IP with anti-USP14 antibody. The complexes were immunoblotted for anti-GABARAP and anti-USP14 antibodies. Red arrow indicates IgG heavy chain band. Blue arrow indicates USP14.In (B and C) right panel represents histogram for the densitometry ratio of GABARAP to USP14 in the pull down.(D) Striatal cells expressing 7Q (control) and 109Q (mutant) Htt were subjected to immunoblotting for GABARAP. Right panel represents histograms for the densitometry ratio of GABARAP-II/GABARAP-I.(E) Striatal cells expressing 7Q and 109Q Htt and transfected with Flag-W58A-USP14 were stimulated with bafilomycin (200 nM, 6 h). Cell lysates were analyzed with IB for anti-GABARAP and anti-Flag.In (B--D) n = 3, p value was calculated by Student\'s t-test. \*\*p ≤ 0.01, \*\*\*p ≤ 0.001. GABARAP- GABA type A receptor-associated protein.Figure 9Mutant W58A-USP14 Increases GABARAP Positive Puncta in a HSC70-dependent Manner(A and B) Striatal cells were transfected with EGFP-GABARAP in combination with an empty vector or Flag-W58A-USP14 and further stimulated with (A) chloroquine (50 μM, 5 h) or (B) VER-155008 (25 μM, 24 h). Live cell imaging was done using EVOS FL microscope revealing EGFP-GABARAP positive autophagosomes. In (A) right panel represents average integrated intensity per GABARAP particles depicted as a histogram. Intensity of GABARAP positive autophagosomal structures was quantified using ImageJ. n = 3. Scale, 100 μM (A and B).(C) Striatal cells were plated on Ibidi ibitreat polymer bottom wells as described in [Transparent Methods](#mmc1){ref-type="supplementary-material"} and transfected with EGFP-GABARAP in combination with an empty vector or Flag-W58A-USP14 and stimulated for 24 h with VER-155008 (25 μM). High-resolution live cell imaging with a Nikon-Eclipse Ti-E inverted wide-field microscope equipped with an environmental chamber was utilized to reveal the EGFP-GABARAP positive autophagosomes, n = 5. Scale, 10 μM.In (A and C) p value was calculated by two-way ANOVA. \*p ≤ 0.05, \*\*p ≤ 0.01, \*\*\*p ≤ 0.001, \*\*\*\*p ≤ 0.0001. EGFP,- enhanced green fluorescent protein.

Discussion {#sec3}
==========

In this work, we demonstrate that USP14 plays a role in regulation of autophagy and UPR in neuronal cells. The basis for this is the ability of USP14 to constitute functional protein-protein interactions with key signaling molecules in the cell. The precise nature of such modules involving USP14 has so far remained elusive except for reports on the binding of USP14 to Beclin-1 ([@bib35]), c-Jun ([@bib31]), and IRE1α ([@bib12]), and the molecular mechanisms associated with these interactions are not fully understood. Using advanced proteomics, we show here that USP14 interacts with the molecular chaperone HSC70 in human neuroblastoma SH-SY5Y cells, which was functionally validated using immunoprecipitation and other experiments. The interaction between USP14 and HSC70 was enhanced by inhibition of the proteasome that reduced the binding of USP14 to the PSMD2 in the proteasome 19S RP. We further noticed that USP14 is able to interact with XBP1u and the ER-resident protein IRE1α. These findings demonstrate that with reduced binding to PSMD2, USP14 can interact with cellular proteins, such as HSC70, XBP1u, and IRE1α. These protein-protein interactions may have functional consequences in various human diseases characterized by accumulation of misfolded proteins and an impaired proteasome function. Particularly in HD and other polyQ diseases, expression of mutant proteins with expanded repeats can block the proteasome and induce ER stress further exacerbating the disease conditions ([@bib11], [@bib12]). Recent work also established that the expanded polyQ repeats inhibit Beclin-1 mediated autophagy ([@bib1]). In this work, we have addressed the functionality of USP14 interactions specifically in the context of striatal neuronal cells expressing mutant Htt protein with dysregulated proteostasis and autophagy. USP14 is a vital component of the proteasome coordinating the deubiquitylation of protein substrates followed by substrate engagement, leading to proteasome activation ([@bib22]). The mammalian 26S proteasome consists of two components, 19S RP and 20S core particle containing several subunits. USP14 binds to the PSMD2/RPN1 protein in the 19S RP via its N-terminal UBL domain ([@bib2]). Using mutagenesis, we have identified tryptophan at position 58 in the UBL domain of USP14 that disrupts the association of USP14 with PSMD2. The UBL-mutant W58A-USP14 behaved similarly to WT-USP14 upon proteasome inhibition indicating that they are functionally related. Results obtained with the W58A-USP14 mutant reinforce the concept of the existence of a dynamic pool of USP14 in the cell, performing proteasome independent functions in the cell.

To investigate the functions of USP14 independent of the proteasome, we first characterized its role in unfolded protein response based on its known interaction with the signaling protein IRE1α ([@bib20]). We have previously reported that USP14 counteracts the IRE1α-mediated ER stress and increases the clearance of mutant Htt in cells ([@bib12]). In this study, we observed that the association of USP14 with IRE1α was further increased upon proteasome inhibition. Using USP14 knockdown cells we noted that USP14 deficiency resulted in an enhanced phosphorylation of IRE1α and a decrease in XBP1 splicing activity. This suggests that USP14 may differentially control the kinase and the RNase domain in IRE1α located at either ends of the molecule. Similar actions on IRE1α involving distinct responses in its structural domains have been reported for small molecule compounds that are ATP-competitive inhibitors that disrupt the IRE1α kinase function while activating the RNase domain ([@bib9]). It would be important to investigate whether the USP14 can serve as a determinant of IRE1α response upon different stimuli.

Subsequently, we noted that USP14 interacts with unspliced XBP1 (XBP1u) protein upon proteasome inhibition. Compared with spliced XBP1 acting as a transcription factor, less is known about XBP1u in cell physiology. Previous reports have shown that XBP1u is a short-lived protein ([@bib30]), and XBP1u, via translational pausing of its nascent polypeptide, mediates efficient splicing of XBP1 mRNA by activated IRE1α upon ER stress ([@bib13], [@bib36]). We observed that inhibition of the proteasome strongly upregulated XBP1u in neuronal cells with accumulation of the protein in aggresome-like induced structures, called here ALIS. These have been observed before in HEK 293T cells with no direct functions reported ([@bib21]). We noted also that XBP1u interacts with USP14 and HSC70, likely forming a tri-partite complex in neuronal cells.

To investigate whether the ALIS are modulated in HD, we studied striatal cells expressing control 7Q or 109Q mutant Htt protein. To our surprise, we noticed that the mutant Htt expressing cells showed less formation of XBP1u positive ALIS upon proteasome inhibition compared with controls. These could be related to lowered levels of USP14 and HSC70 in the mutant cells. Treatment with the HSC70 inhibitor, VER-155008, reduced the formation of the ALIS in control striatal cells upon proteasome inhibition. Together, these findings indicate that ALIS formation is reduced in mutant Htt expressing cells and that USP14 along with HSC70 could be involved in their dynamics. Further studies are warranted to pinpoint the functions of the XBP1u positive ALIS in cell responses and in various diseases, such as HD.

HSC70 is a molecular chaperone that affects diverse cellular pathways by regulating protein folding and degradation of misfolded proteins. These processes are prone to dysfunction in human disorders with accumulation of misfolded or mutant proteins. In proteostasis, HSC70 is involved in the disaggregation of misfolded protein, in chaperone-mediated autophagy and in microautophagy ([@bib29]). USP14 binds Beclin-1 and inhibits the formation of autophagosomes by removing the K63-linked poly-ubiquitin chains on Beclin-1 ([@bib35]). We hypothesized that USP14 along with HSC70 may play a role in modulating autophagy. For this purpose, we focused on GABARAP and its functions in autophagic processes. There are three ATG8 gene subfamilies in mammals, namely, microtubule-associated protein 1 light chain 3 (LC3), γ-aminobutyric-acid-receptor-associated protein (GABARAP), and Golgi-associated ATPase enhancer of 16 kDa (GATE-16) ([@bib28]). GABARAP/GATE-16 is required for the formation of autophagosomes and their maturation ([@bib33], [@bib34]), and further they can regulate GABA~A~ receptor endocytosis, thus influencing neuronal signaling function ([@bib10]). The GABAergic medium spiny neurons in the striatum are particularly affected in HD. Hence, we investigated whether GABARAP along with USP14 and HSC70 could specifically have relevance in striatal neuronal cells expressing Htt.

To begin with, we noted that USP14 in the striatal cells expressing mutant Htt was decreased both at the mRNA and protein levels. The former may be related to reduced transcription, as accumulation of mutant Htt in the nucleus is known to affect gene expression; however, this warrants further investigation. We further observed that the protein levels of HSC70 were downregulated in the mutant Htt-expressing cells, and these cells were also more vulnerable to the action of VER-155008 inhibiting the activity of HSC70. These findings may indicate a possible role of HSC70 and its interaction with USP14 in the pathophysiology of HD. We further observed that the UBL-mutants, W58A-USP14 and WT-USP14, upon proteasome inhibition could interact with GABARAP in neuronal cells. Striatal neuronal cells expressing mutant Htt exhibited reduced conversion of GABARAP-I to its mature form, GABARAP-II. This indicated a possible defect in the GABARAP-mediated autophagosome maturation. To further characterize the physiological relevance of this we performed live cell imaging and tracking of EGFP-GABARAP positive autophagosomes in 7Q Htt and 109Q Htt expressing cells. Data showed that the formation of EGFP-GABARAP positive autophagosomes was downregulated in mutant Htt cells compared with control. Inhibition of lysosomes with chloroquine revealed that the mutant Htt-expressing cells exhibited a defect in GABARAP autophagosome biogenesis resulting in the reduced formation of these structures.

Overexpression of the UBL mutant, W58A-USP14, enhanced the formation of GABARAP positive autophagosomes in the striatal cells but also affected their clearance as demonstrated by using chloroquine. Most importantly, treatment with VER-155008 abrogated the USP14-mediated increase in GABARAP positive autophagosomal structures, signifying involvement of HSC70 in this process. Our findings indicate that HSC70 may have additional functions in the autophagy process beyond its established role in regulation of chaperone-mediated autophagy and microautophagy. Further studies are warranted to understand the dynamics of GABARAP and the importance of HSC70 and USP14 in autophagosome maturation.

In conclusion, we have identified proteasome-independent functions of USP14 in neuronal cells. USP14 interacts with the chaperone HSC70 and the protein XBP1u with functional consequences for coordination of ER signaling, upon proteasome inhibition and formation of GABARAP positive autophagosomes. We propose that the interaction of USP14 with HSC70 studied here can be considered a molecular hub for mediating crosstalk between the proteasome, ER stress signals, and autophagy in the cell (cartoon in graphical abstract). This hub could be a target for future drug development in different diseases including HD. Impairment of protein degradation involving the proteasomes as well as autophagy are key features of several human diseases including HD. Our results, using mutant Htt-expressing striatal neuronal cells, indicate that these cells have a defect in autophagy at the GABARAP sensitive stage of autophagosome maturation that can be influenced by USP14 and HSC70 proteins. Modulation of the USP14-HSC70 axis using different compounds could be a target for future drug development in neurodegenerative diseases including HD.

Limitations of the Study {#sec3.1}
------------------------

Protein homeostasis (proteostasis) is crucial for proper cell function and viability and is known to be dysfunctional in several human diseases including cancer and neurodegenerative disorders. In our study, we have employed proteomic analyses and cell cultures to depict a role of the deubiquitinating enzyme USP14 in the control of proteostasis pathways via interaction with the chaperone, HSC70. Thereby we used a cell model to investigate the dysregulation of proteostasis and autophagy in Huntington disease. Further functional studies and *in vivo* models of HD and other disorders are required to confirm the precise role of the USP14-HSC70 axis in neuronal autophagy and in ER signaling as a possible target for modifying disease pathology.
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All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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